Notably, the RPL29 and MBP fragment peptides 135–149 and 168–177, respectively, are listed in SPENCER as tumor-specific for various cancers [55,56,57], suggesting their potential as novel neoantigens for immunotherapeutic strategies. This evidence concerns the gene MBP and cancer.